General factors influencing drug delivery to the lung
| Autor: | D. Ganderton |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Inhalation business.industry medicine.drug_class Nebulizers and Vaporizers Inhaler Anti-Inflammatory Agents medicine.disease Asthma Dry-powder inhaler Bronchodilator Agents Drug Delivery Systems Anesthesia Bronchodilator Administration Inhalation Drug delivery medicine Humans Steroids Intensive care medicine business Lung Application methods |
| Zdroj: | Respiratory Medicine. 91:13-16 |
| ISSN: | 0954-6111 |
| DOI: | 10.1016/s0954-6111(97)90099-8 |
| Popis: | The first devices to be developed for the delivery of bronchodilators and corticosteroids for the treatment of asthma were the pressurised metered dose inhalers (pMDIs). While pMDIs are viewed as patient friendly, they are associated with some serious disadvantages, such as considerable oropharyngeal deposition (due to the speed of delivery of the dose) and poor patient co-ordination of inhalation and activation. This has resulted in the development of alternative systems, such as the dry powder inhaler (DPI). However, DPIs also have problems, as there are difficulties in handling, measuring and metering fine particles. New devices, such as the Easi-breathe™ and Diskus™ inhalers, are now being introduced to overcome some of these problems. The ideal device is one that will produce a large proportion of respirable particles in the emitted dose. It must also deliver precise and uniform doses of drug to the patient. Further innovations are required to achieve these goals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect